18-MC

18-Methoxycoronaridine (18-MC) is a derivative of ibogaine invented in 1996 by the team around the pharmacologist Stanley D. Glick from the Albany Medical College and the chemist Martin E. Kuehne from the University of Vermont. In animal studies it has proved to be effective in suppressing self-administration of morphine, nicotine, alcohol, and methamphetamine.

History[edit | edit source]

18-MC was first synthesized in the lab of Martin Kuehne in 1996. The goal was to create a compound that could treat addiction without the hallucinogenic effects of ibogaine. The team of Stanley Glick and Martin Kuehne achieved this by altering the ibogaine molecule, removing a methoxy group and adding one at a different point, which resulted in 18-MC.

Pharmacology[edit | edit source]

18-MC is a sigma receptor antagonist and nicotinic acetylcholine receptor antagonist. It is believed to act primarily on the α3β4 nicotinic acetylcholine receptors in the brain, which are believed to be involved in addiction to several different substances.

Clinical trials[edit | edit source]

In 2018, the company MindMed started a phase 1 clinical trial for 18-MC as a potential treatment for opioid addiction. The trial is expected to be completed in 2021.

References[edit | edit source]

External links[edit | edit source]

Clinical trial of 18-MC

18-MC Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.